 everybody also on my behalf. I think I have the privilege of being one of the first Finnish speakers, so welcome to Helsinki everybody. And I said I run a company called Blueprint Genetics and up on the screen there's a question, can I get tested at Blueprint Genetics? And this is a question I hear a lot, friends, acquaintances all the time, so that can I send my sample to Blueprint Genetics. And I always feel a little painful saying that, well, sort of kind of, you know, no, because we work together with university hospitals, so that we are a clinical genetic testing company. And that's how it is, so sort of by regulation based on our terms, everybody who sends us a sample for genetic testing is required to be a healthcare professional. This is a personal health session, so I'm just going to spend the next 10 minutes on my view of how certain things from the clinical space will be brought into the personal health management. And it's good to understand that this is sort of a hot topic in our own field, so consumer genetic testing is quite separate field from the clinical sort of clinical grade advanced genetic testing. And there's a lot of tension between these two worlds, but we are now seeing them going closer to each other. And I think it's pretty exciting to see. And if we go back a little, the past, say, 10 years have seen a huge development in technology in genetics. So both laboratory methods, data analytics, data science, they've made huge advancements. And basically, it's very fair to say that the genetics revolution and everything that was expected has huge development in that field. It already is here, but it's in the clinical side of things. So it hasn't yet reached the consumer. And many of you know 23andMe, Ancestral DNA, perhaps. These are very well known consumer genetics companies where the volumes are growing very significantly. But it's still, as I said, it's a very separate field. If we think about what we can do in the clinical space, there's so much more. So it's very advanced, whereas if we look at these consumer tests, they only provide a very small glimpse, ancestry, certain individual risks for everybody. But in the clinical space, because we don't have the same validation requirements, there's so much more that we can tell about the DNA. And we think that this sort of a gap will start bridging. Or if we just look around, I can name easily 15 companies who are starting to provide clinical genetic testing for health individuals. So that is the big change that instead of just looking at patients with symptoms, clinical genetic testing companies in 2018 will start providing certain kind of advanced clinical tests also for health individuals. And this is a great change in the industry, or a big change in the industry. And what enables it is that if we traditionally look at the consumer genetic testing space, there's very high validation requirements. So everything that you do needs to be very thoroughly tested. And that is, of course, a good thing. And it's part of a responsible practice. But now we see a model emerging where, in a way, the referral mechanism and the counseling mechanism of the clinical space, so that there needs to be a healthcare professional who does the referral of the test. And there needs to be a genetic counselor who explains the results to the individual. We see these elements becoming available for health individuals, consumers overall. And that's what we expect to see in 2018. So that these clinical tests, with a slight difference in the provision model, will be available for health individuals. And thinking briefly, what's there in the road map? So what will be available starting in a way this year, next year, when this model changes? First of all, key risks in a much broader sense than what today's consumer genetic testing gives you. Predisposition for more severe hereditary disorders. So roughly, there's estimates that about 5% of us are in significant risk for a more severe hereditary disorder. And this kind of testing will be more and more available. There's a couple of very clear options of pharmacogenetics. So different people metabolize drugs differently. And this is an existing test that you can buy already with a couple of hundred of dollars. But it's a very useful test. So just to tell that whether a drug has no effect at all, or whether there's negative effects with a drug. Then there's carrier screening. So for family planning purposes, if there's recessive mutations, all of us carry recessive disorders. And the idea is to understand whether both of the parents are carrying the same mutation or not. And these are now, at least, if you look at the two latter, these are tests that you can buy already today with a couple of hundred, if you know where to look from. But just with the advance of sequencing technology and everything, we just see next year all of this coming together. So most likely there will be just general tests available where everything that's allowed in a way from a validation perspective or regulation perspective, everything is bundled up into one test. And maybe thinking that what's needed to drive personal genetics further. I mean, the sort of, as I said, these are very different worlds, the clinical testing and consumer testing. And the fact is that they are going closer to each other, and we just see it happening all the time. So if we think about what needs to happen for that to go further, I think, first of all, the clinical genetics testing still needs to develop. So the volumes need to develop. So the more we gather data with the patients, the more we are able to give in a safe and responsible manner, we're able to give conclusions for healthy individuals. So I think the basic thing is just for the clinical testing engine, so to say, just to develop further volumes go up. I think that's the first thing. It's also good to understand that in addition of consumer genetics, clinical genetics, there's the personalized medicine sort of a trend. And that's today widely about somatic cancer treatments and the DNA sequencing related to that. But all of these three fields are working together in a way, at least working towards the same goal. And if we think about, from a blueprint genetics point of view, in the clinical genetic testing space, what should happen? I think we need to promote the patient more so thinking where we are today, we work together with physicians. And in a way, we are very backseat in the process, which in a way is good. And what I think what we would need to do is understand that actually we can provide more information to the patients themselves. We can do better communications there. And that on the other hand creates awareness among patient associations, also with the patient families. And I believe that this is good for the industry because whether clinical providers like us, wanted or not, these two worlds of consumer genetics and clinical genetics, they are going closer to each other. There's a few other things. We just think about the barriers overall. In the personal health space, this is a health, it's a so-called self-pay space. So patients, individuals, they pay out of their own pocket for the products and services. But if we think about clinical genetic testing, for example, with blueprint, I think 99% of our revenue is paid by the healthcare system. And there's a lot of barriers in the healthcare systems for genetic testing still today. And I think removing those barriers, it's a hot topic also in our industry. I think that drives the clinical genetic testing space further quite a lot, which then, on the other hand, helps the consumer space or the personal genetic space. There's a long list of things, data protection, I think. It's a never-ending topic, digital health and data protection and all this. And it seems to be quite exhausting to come up with good frameworks or handle the whole regulatory side of things well. But I think those efforts really should be made because they really push further us, for example, being able to put the patient in the focus. And analytics, it's a broad term, but if we think about genetics, looking at the past couple of years, there's been a huge amount of money going into the funding of young companies. And it's not for no reason. There's years ahead of a lot of challenging efforts in the data science part of things. So whether it's supervised artificial intelligence, data science, there's just many different problems to be solved in that space. And I think that's the one sort of a technological side where things are still developing in a very rapid pace. And sum up. So thinking that this is a personal health session, it's good to understand that the consumer genetic space is still today, it's very different. There's so much more that we can do in the clinical genetic testing space. And I think 2018 is the year when we start seeing these two worlds go closer together. And and that that sort of that changes is driven by the, in a way, a regulatory model where both the referral of the health care professional and the genetic counseling of a professional is incorporated into the ordering process. So the patients or the health individuals are not working directly with the with the test provider, but rather there are still the elements of a professional referral and a professional genetic counseling involved. And patient access, I think this is this is key in a way for the clinical testing space to get closer to the consumer space for personal health space. So in addition, just for creating awareness and so forth, I think it it would force companies like us to just structure things more towards the patient. So putting the patient in the center. So I think this is this is definitely something that the clinical space should do. And I think the last last part, even though there has been so much of technological progress in the genetic space, laboratory methods have gone, gone forward tremendously bloop in started as a laboratory company. I think the challenge today is more and more in the software and data science side of things. And there's years of really, really challenging efforts there. So anybody of thinking about a company, I think the whole genetic space is quite vast. And all you have to do is find your own own space, because there's a lot of problems to be solved. And I guess that was also the topic of this conference. Thank you.